
Novavax (NVAX) Stock Forecast & Price Target
Novavax (NVAX) Analyst Ratings
Bulls say
Novavax is positioned favorably because Matrix-M appears to be a differentiated, human-use adjuvant with a potentially safer profile and broad applicability, which can support both internal pipeline development and high-value external partnerships across infectious disease and oncology. Its collaboration momentum is notable, with four top-ten global pharmaceutical companies and 30+ unique fields under exploration, while Nuvaxovid’s commercial profile remains attractive through high-teens to low-20s royalties, encouraging Q1:26 sales of €16MM, and projected 19% to 26% standalone COVID-19 market share by 2030. The outlook is further supported by an estimated $40-50MM in 2026 product supply sales and a target for a $200MM core-expense run-rate, which together suggest improving operating leverage and multiple avenues for value creation.
Bears say
Novavax is viewed negatively because its core COVID-19 vaccine opportunity appears to be shrinking, with surveyed physicians expecting an 11% decline in vaccinated U.S. adults in the 2026-27 season and IQVIA Rx data indicating roughly a 26% decline in COVID-19 vaccine prescriptions through 12/26/25. At the same time, new FDA/CDC guidelines implemented in '25 limit access for people without risk factors, while market-share expectations for Nuvaxovid in 2030 remain only 19% from physicians and 26% from payors, underscoring constrained commercial upside. Beyond demand pressure, the company still faces typical biotech risks—clinical safety surprises, regulatory delays, IP challenges, and failure to develop a successful combo or variant-specific boosters—making execution and valuation highly uncertain.
This aggregate rating is based on analysts' research of Novavax and is not a guaranteed prediction by Public.com or investment advice.
Novavax (NVAX) Analyst Forecast & Price Prediction
Start investing in Novavax (NVAX)
Order type
Buy in
Order amount
Est. shares
0 shares